Skip to main content
Figure 1 | Pediatric Rheumatology

Figure 1

From: Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis

Figure 1

Time to steroid discontinuation and time on remission up to the first relapse on Adalimumab. a. Survival curves of time to steroid discontinuation (months) for the Group 1 (black curve), receiving Adalimumab, as first anti-TNFα therapy, and the Group 2 (grey curve), receiving Adalimumab as second anti-TNFα therapy. On the y-axis, the probability of patient being on steroid treatment is shown. (log-rank, Mantel-Cox χ2 4.12, p < 0.004). b. Survival curves up to the first uveitis relapse on therapy after achieving remission (months) for Group 1 (black curve), receiving Adalimumab as first anti-TNFα therapy, and Group 2 (grey curve), receiving Adalimumab as second anti-TNFα therapy. On the y-axis, the probability of patient being on remission on anti-TNF-α therapy is shown (log-rank, Mantel-Cox χ2 10.12, p < 0.002).

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096